ReviewFrontiers in oncology2017
Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era.
Review in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Longitudinal plasma nano-proteomics reveals acute systemic responses to radiotherapy and predictive biomarkers of late toxicity.Communications medicine · 2026Article
- Assessment of the predictive power the radiation-induced lymphocyte apoptosis method in prostate cancer patients.Scientific reports · 2025Article
- Evaluation of clinical trials addressing supportive care measures for management of acute and chronic radiation toxicities.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Long-term outcome of definitive radiotherapy for locally advanced non-small cell lung cancer: A real-world single-center study in the pre-durvalumab era.Cancer medicine · 2024Article
- Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.Seminars in radiation oncology · 2023Review
- Article
- Precision based approach to tailoring radiotherapy in the multidisciplinary management of pediatric central nervous system tumors.Journal of the National Cancer Center · 2023Review
- Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy.British journal of cancer · 2023Article
- Improving Patients' Life Quality after Radiotherapy Treatment by Predicting Late Toxicities.Cancers · 2022Review
- Identification of Risk Loci for Radiotoxicity in Prostate Cancer by Comprehensive Genotyping ofCancers · 2021Article
- Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021Article
- Late Sequelae of Radiotherapy—The Effect of Technical and Conceptual Innovations in Radiation Oncology.Deutsches Arzteblatt international · 2021Review
- Liquid biopsy in NSCLC: a new challenge in radiation therapy.Exploration of targeted anti-tumor therapy · 2021Review
- Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.Journal of the National Cancer Institute · 2020Article
- A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort.Frontiers in oncology · 2020Article
- Use of genomics to balance cure and complications.Nature reviews. Clinical oncology · 2020Article
- Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity.Clinical and translational radiation oncology · 2019Article
- Progressive breast fibrosis caused by extreme radiosensitivity: Oncocytogenetic diagnosis and treatment by reconstructive flap surgery.Cancer reports (Hoboken, N.J.) · 2019Article
- Individual Radiosensitivity in Oncological Patients: Linking Adverse Normal Tissue Reactions and Genetic Features.Frontiers in oncology · 2019Article
- Applying Precision Oncology Principles in Radiation Oncology.JCO precision oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
The ability to stratify patients using a set of biomarkers, which predict that toxicity risk would allow for radiotherapy (RT) modulation and serve as a valuable tool for precision medicine and personalized RT. For patients presenting with tumors with a low risk of recurrence, modifying RT schedules to avoid toxicity would be clinically advantageous. Indeed, for the patient at low risk of developing radiation-associated toxicity, use of a hypofractionated protocol could be proposed leading to treatment time reduction and a cost-utility advantage. Conversely, for patients predicted to be at high risk for toxicity, either a more conformal form or a new technique of RT, or a multidisciplinary approach employing surgery could be included in the trial design to avoid or mitigate RT when the potential toxicity risk may be higher than the risk of disease recurrence. In addition, for patients at high risk of recurrence and low risk of toxicity, dose escalation, such as a greater boost dose, or irradiation field extensions could be considered to improve local control without severe toxicities, providing enhanced clinical benefit. In cases of high risk of toxicity, tumor control should be prioritized. In this review, toxicity biomarkers with sufficient evidence for clinical testing are presented. In addition, clinical trial designs and predictive models are described for different clinical situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.